Researchers found that children and young adults with intermediate- and high-risk B-cell acute lymphoblastic leukemia who received blinatumomab after induction therapy had significantly improved two-year, progression-free and overall survival compared with those who were given chemotherapy. The findings were presented at the American Society of Hematology's annual meeting.
Blinatumomab may benefit youths with B-cell ALL
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.